CYAD - Celyad shares surge ahead of upcoming multiple myeloma study poster presentation

Celyad Oncology (CYAD) shares rise nearly 20% during premarket trading after the company's abstract highlighting initial data from an early-stage trial of multiple myeloma treatment CYAD-211 was accepted for e-poster presentation at the upcoming European Hematology Association ((EHA)) Virtual Congress.CYAD-211 is an investigational, non-gene edited allogeneic CAR T candidate in development for the treatment of relapsed/refractory multiple myeloma.The open-label, dose-escalation trial will evaluate the safety and clinical activity of CYAD-211 following cyclophosphamide and fludarabine preconditioning chemotherapy in patients with the condition.The company highlighted that no grade ? 3 treatment-related adverse events nor evidence of Graft-versus-Host disease were reported from the completed first dose-level ((DL1)) cohort of the phase 1 study.Initial clinical activity was observed, with one confirmed partial response ((PR)) case observed in the low dose (30x106 cells per infusion), Celyad said.The e-poster under the title "Objective response at low dose in the first-in-human IMMUNICY-1 trial evaluating non-gene edited allogeneic CYAD-211 anti-BCMA CAR T product in relapsed

For further details see:

Celyad shares surge ahead of upcoming multiple myeloma study poster presentation